Cargando…

EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN

PURPOSE: To evaluate the efficacy and safety of intravitreal aflibercept injection (IAI) in Japanese patients with diabetic macular edema (DME). METHODS: VIVID-DME was a Phase 3 study comprising patients with DME randomized 1:1:1 to IAI 2 mg every 4 weeks (2q4), IAI 2 mg every 4 weeks until Week 16...

Descripción completa

Detalles Bibliográficos
Autores principales: Terasaki, Hiroko, Shiraki, Kunihiko, Ohji, Masahito, Metzig, Carola, Schmelter, Thomas, Zeitz, Oliver, Sowade, Olaf, Kobayashi, Masato, Vitti, Robert, Berliner, Alyson, Shiraga, Fumio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Retina 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510325/
https://www.ncbi.nlm.nih.gov/pubmed/29470308
http://dx.doi.org/10.1097/IAE.0000000000002100
_version_ 1783417403750744064
author Terasaki, Hiroko
Shiraki, Kunihiko
Ohji, Masahito
Metzig, Carola
Schmelter, Thomas
Zeitz, Oliver
Sowade, Olaf
Kobayashi, Masato
Vitti, Robert
Berliner, Alyson
Shiraga, Fumio
author_facet Terasaki, Hiroko
Shiraki, Kunihiko
Ohji, Masahito
Metzig, Carola
Schmelter, Thomas
Zeitz, Oliver
Sowade, Olaf
Kobayashi, Masato
Vitti, Robert
Berliner, Alyson
Shiraga, Fumio
author_sort Terasaki, Hiroko
collection PubMed
description PURPOSE: To evaluate the efficacy and safety of intravitreal aflibercept injection (IAI) in Japanese patients with diabetic macular edema (DME). METHODS: VIVID-DME was a Phase 3 study comprising patients with DME randomized 1:1:1 to IAI 2 mg every 4 weeks (2q4), IAI 2 mg every 4 weeks until Week 16 then 8-week dosing (2q8), and laser. A total of 403 patients (76 Japanese) were included in this study. VIVID-Japan (72; all Japanese patients) was a nonrandomized, open-label study comprising Japanese patients with DME receiving IAI 2q4 until Week 16, then 2q8. Primary efficacy endpoint (Week 52) of VIVID-DME was mean change from baseline in best-corrected visual acuity; VIVID-Japan evaluated safety and tolerability. RESULTS: Mean change in best-corrected visual acuity (letters) for 2q4, 2q8, and laser groups was +10.6, +10.9, and +1.2 and +9.8, +9.5, and +1.1 in the non-Japanese and Japanese populations of VIVID-DME, respectively. In VIVID-Japan, it was +9.3 for IAI 2q8. Intravitreal aflibercept injection also provided consistently greater benefits for anatomical outcomes versus laser. Adverse events were consistent with the known safety profile of IAI. CONCLUSION: In Japanese patients with DME, IAI treatment was superior to laser for visual and anatomical outcomes and resulted in efficacy and safety outcomes similar to those in a non-Japanese patient population.
format Online
Article
Text
id pubmed-6510325
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Retina
record_format MEDLINE/PubMed
spelling pubmed-65103252019-07-22 EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN Terasaki, Hiroko Shiraki, Kunihiko Ohji, Masahito Metzig, Carola Schmelter, Thomas Zeitz, Oliver Sowade, Olaf Kobayashi, Masato Vitti, Robert Berliner, Alyson Shiraga, Fumio Retina Original Study PURPOSE: To evaluate the efficacy and safety of intravitreal aflibercept injection (IAI) in Japanese patients with diabetic macular edema (DME). METHODS: VIVID-DME was a Phase 3 study comprising patients with DME randomized 1:1:1 to IAI 2 mg every 4 weeks (2q4), IAI 2 mg every 4 weeks until Week 16 then 8-week dosing (2q8), and laser. A total of 403 patients (76 Japanese) were included in this study. VIVID-Japan (72; all Japanese patients) was a nonrandomized, open-label study comprising Japanese patients with DME receiving IAI 2q4 until Week 16, then 2q8. Primary efficacy endpoint (Week 52) of VIVID-DME was mean change from baseline in best-corrected visual acuity; VIVID-Japan evaluated safety and tolerability. RESULTS: Mean change in best-corrected visual acuity (letters) for 2q4, 2q8, and laser groups was +10.6, +10.9, and +1.2 and +9.8, +9.5, and +1.1 in the non-Japanese and Japanese populations of VIVID-DME, respectively. In VIVID-Japan, it was +9.3 for IAI 2q8. Intravitreal aflibercept injection also provided consistently greater benefits for anatomical outcomes versus laser. Adverse events were consistent with the known safety profile of IAI. CONCLUSION: In Japanese patients with DME, IAI treatment was superior to laser for visual and anatomical outcomes and resulted in efficacy and safety outcomes similar to those in a non-Japanese patient population. Retina 2019-05 2018-02-21 /pmc/articles/PMC6510325/ /pubmed/29470308 http://dx.doi.org/10.1097/IAE.0000000000002100 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Study
Terasaki, Hiroko
Shiraki, Kunihiko
Ohji, Masahito
Metzig, Carola
Schmelter, Thomas
Zeitz, Oliver
Sowade, Olaf
Kobayashi, Masato
Vitti, Robert
Berliner, Alyson
Shiraga, Fumio
EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN
title EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN
title_full EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN
title_fullStr EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN
title_full_unstemmed EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN
title_short EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN
title_sort efficacy and safety outcomes of intravitreal aflibercept focusing on patients with diabetic macular edema from japan
topic Original Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510325/
https://www.ncbi.nlm.nih.gov/pubmed/29470308
http://dx.doi.org/10.1097/IAE.0000000000002100
work_keys_str_mv AT terasakihiroko efficacyandsafetyoutcomesofintravitrealafliberceptfocusingonpatientswithdiabeticmacularedemafromjapan
AT shirakikunihiko efficacyandsafetyoutcomesofintravitrealafliberceptfocusingonpatientswithdiabeticmacularedemafromjapan
AT ohjimasahito efficacyandsafetyoutcomesofintravitrealafliberceptfocusingonpatientswithdiabeticmacularedemafromjapan
AT metzigcarola efficacyandsafetyoutcomesofintravitrealafliberceptfocusingonpatientswithdiabeticmacularedemafromjapan
AT schmelterthomas efficacyandsafetyoutcomesofintravitrealafliberceptfocusingonpatientswithdiabeticmacularedemafromjapan
AT zeitzoliver efficacyandsafetyoutcomesofintravitrealafliberceptfocusingonpatientswithdiabeticmacularedemafromjapan
AT sowadeolaf efficacyandsafetyoutcomesofintravitrealafliberceptfocusingonpatientswithdiabeticmacularedemafromjapan
AT kobayashimasato efficacyandsafetyoutcomesofintravitrealafliberceptfocusingonpatientswithdiabeticmacularedemafromjapan
AT vittirobert efficacyandsafetyoutcomesofintravitrealafliberceptfocusingonpatientswithdiabeticmacularedemafromjapan
AT berlineralyson efficacyandsafetyoutcomesofintravitrealafliberceptfocusingonpatientswithdiabeticmacularedemafromjapan
AT shiragafumio efficacyandsafetyoutcomesofintravitrealafliberceptfocusingonpatientswithdiabeticmacularedemafromjapan